Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

BBMP has implemented a streamlined process, allowing citizens to obtain final e-khata within two days after application ...

by week 24, indicating an improvement in a key indicator of kidney health. Importantly, ARO-C3 was generally well-tolerated by patients, with no serious treatment-emergent adverse events or ...

Liverpool ta tuntubi makusantan dan wasa mai kai hari na Newcastle da Sweden Alexander Isak, mai shekara 25, kafin komawarsa ...

Valaris is set to hit $61.50 in 24 months with improved fleet management, rising day rates, and strategic positioning ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Mining shares closed higher in the Thursday's session. Oriental Trimex Ltd.(up 5.02%), Gujarat Mineral Development ...